Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli
Inventors
Yoon, Seong Jun • Son, Jee Soo • KIM, In Hwang • Paik, Hyoung Rok • IM, Hyun Joo • YU, Hyun Jin • AHN, Cheol • KIM, TAE YEOL • JUN, Soo Youn • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11596659-B2
Publication Date
2023-03-07
Expiration Date
Abstract
A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.
Core Innovation
The invention relates to a composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli. The composition comprises a Myoviridae bacteriophage Esc-COP-18 that has an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1, together with a pharmaceutically acceptable carrier. The phage is deposited in the Korean Collection for Type Cultures under accession number KCTC 14028BP.
Esc-COP-18 is characterized by a latent period of 25-35 minutes and a burst size of 145-195 plaque-forming units (PFU)/infected cell. The bacteriophage has major structural proteins in the sizes of approximately 37 kDa, 48 kDa, 75 kDa, and 135 kDa. The bacteriophage concentration is defined as 1×10^4 PFU/ml to 1×10^15 PFU/ml, or 1×10^4 PFU/g to 1×10^15 PFU/g.
The invention further provides a method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli. The method includes administering to a subject the Myoviridae bacteriophage Esc-COP-18 and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage Esc-COP-18. The method is bound to Esc-COP-18 defined by the genome represented in SEQ ID NO: 1 and by the same latent period, burst size, deposition/accession number, major structural protein sizes, and concentration ranges.
Claims Coverage
The document provides two independent claims. Each independent claim centers on a specifically characterized Myoviridae bacteriophage, Esc-COP-18, defined by sequence, deposition, biological performance parameters, structural protein sizes, and a defined concentration range, used either in a composition or in a method of administration and lysis.
Phage composition with defined Esc-COP-18 characteristics for preventing or treating pathogenic E. coli infections
A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli, comprising a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1, and a pharmaceutically acceptable carrier, wherein Esc-COP-18 has a latent period of 25-35 minutes, a burst size of 145-195 PFU/infected cell, is deposited in KCTC under accession number KCTC 14028BP, has major structural proteins of approximately 37 kDa, 48 kDa, 75 kDa, and 135 kDa, and has a concentration of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g.
Method using administration and lysis by defined Esc-COP-18 for preventing or treating pathogenic E. coli infections
A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli, comprising administering to a subject a Myoviridae bacteriophage Esc-COP-18 and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage Esc-COP-18, wherein Esc-COP-18 has a genome represented by a sequence as set forth in SEQ ID NO: 1, has a latent period of 25-35 minutes and a burst size of 145-195 PFU/infected cell, is deposited in KCTC under accession number KCTC 14028BP, has major structural proteins of approximately 37 kDa, 48 kDa, 75 kDa, and 135 kDa, and has a concentration of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g.
The claim set is directed to a defined phage, Esc-COP-18, characterized by the genome sequence SEQ ID NO: 1, deposition as KCTC 14028BP, latent period and burst size ranges, major structural protein size set, and a concentration range, used either as a pharmaceutically acceptable composition for preventing or treating pathogenic Escherichia coli infections or as a method involving administration and lysis.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?